| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/12/2004 | US20040156910 Phytochemicals for treatment of mastalgia and endometriosis |
| 08/12/2004 | US20040156908 Prevention of indwelling device related infection: composition and methods |
| 08/12/2004 | US20040156901 Pharmaceutical composition of topiramate |
| 08/12/2004 | US20040156900 core of an active agent and a swelling agent, and a coating of film forming polymer, which swells when it imbibes fluid from the core and ruptures to release the drug in a pulse in a reliable manner |
| 08/12/2004 | US20040156899 Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| 08/12/2004 | US20040156898 minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have |
| 08/12/2004 | US20040156897 in association with a polymer; produces a Cmax that is statistically significantly lower than the Cmax produced by a delayed release divalproex sodium tablet; minimnizes the variation between peak and trough plasma levels over a 24 hour period |
| 08/12/2004 | US20040156896 Oral controlled release dosage form |
| 08/12/2004 | US20040156895 Solid dosage forms comprising pullulan |
| 08/12/2004 | US20040156894 such as citric acid, maleic acid, tartaric acid or hydrochloric acid; reduces disintegration time for water insoluble, solid, lyophilized, oral pharmaceutical dosage forms |
| 08/12/2004 | US20040156893 Method for treating hypothyroidism |
| 08/12/2004 | US20040156892 Soft shell gelatin capsules containing non-steroidal anti-inflammatories |
| 08/12/2004 | US20040156891 gradient loading procedure, at a pH that prevents precipitation of the drug from the loading solution; preparing giant multivesicular liposomes with high drug-to-lipid ratios; provide long term analgesia. |
| 08/12/2004 | US20040156890 Polycationic sterol derivatives as transfection agents |
| 08/12/2004 | US20040156889 transmembrane pH gradient; protonated form of the drug not capable of permeating liposome membrane, unprotonated form can penetrate; product has a lower inside/higher outside pH gradient and preferably a high drug:lipid ratio |
| 08/12/2004 | US20040156888 lipophobic drug encapsulated in a liposome; elimination half-life of the therapeutic agent when administered as part of the formulation is less than about 14 hours in a rat. |
| 08/12/2004 | US20040156887 Stabilized dispersion of phytosterol in oil |
| 08/12/2004 | US20040156877 Skin conditioner |
| 08/12/2004 | US20040156874 Urea- a topical anti-inflammatory |
| 08/12/2004 | US20040156873 Topically Bioavailable Acne and Rosacea Treatment Compositions |
| 08/12/2004 | US20040156871 hydrophilic/hydrophobic solubilizer such as polyoxyethanyl-sitosterol sebacate, polyoxyethanyl-cholesteryl sebacate or polyoxyethanyl- alpha-tocopheryl sebacate with a polyene macrolide antibiotic or a polyunsaturated fatty acid oil |
| 08/12/2004 | US20040156870 administering urea to the affected area of human skin either before, after or with a topical anti-inflammatory drug. |
| 08/12/2004 | US20040156857 particularly glucosamine HCL or glucosamine sulfate with egg from a bird hyperimmunized with an immunogenic or genetic vaccine; reducing or preventing the onset of osteoarthritis and rheumatoid arthritis |
| 08/12/2004 | US20040156855 Agents for promoting fattening of animals and method of promoting fattening |
| 08/12/2004 | US20040156848 Therapeutic uses of factors which inhibit or neutralize MIF activity |
| 08/12/2004 | US20040156840 A preferred IgM is autoantigen IgM, in particular anti-ds-DNA and anti-phospholipid IgM; may be mixed with an antiinflammatory agent, an immunosuppressive agent and/or a cytostatic agent |
| 08/12/2004 | US20040156836 combination of coenzyme Q and a surfactant can prevent ascites even when administering in a small dose and within a short period of time |
| 08/12/2004 | US20040156825 Short immunomodulatory oligonucleotides |
| 08/12/2004 | US20040156819 Exposing tissue to a prepolymerized chain extended, coupled or crosslinked polyesterether block copolymer; biodegradable |
| 08/12/2004 | US20040156799 Cancer treatment method and compositions |
| 08/12/2004 | US20040156792 Pharmaceutical formulation with an insoluble active agent |
| 08/12/2004 | US20040156791 Heating antipsychotic drug to vaporize; cooling to form condensation aerosol; kit for dispensing thin coating |
| 08/12/2004 | US20040156790 Delivery of drug esters through an inhalation route |
| 08/12/2004 | US20040156789 Delivery of antihistamines through an inhalation route |
| 08/12/2004 | US20040156788 Delivery of erectile dysfunction drugs through an inhalation route |
| 08/12/2004 | US20040156787 Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic theraphy and in vivo diagnostic |
| 08/12/2004 | US20040156783 Complexes of cyanine, indocyanine, phthalocyanine, rhodamine, oxazine, thiazine, phenoselenazines, fluoresceins, porphyrin, squaraine, corrins, croconium, azo, methine and/or indolenium dye linked with receptor binding molecules; tumors |
| 08/12/2004 | US20040154549 Method for supplying bioavailable methionine to a cow |
| 08/12/2004 | DE10328003A1 Composition for treating fish infections caused by parasitic protozoa, fungi and bacteria comprises 1-aza-3,7-dioxabicyclo(3.3.0)octane or its aliphatic substituted derivatives |
| 08/12/2004 | DE10303900A1 Synergistic cholesterol lowering composition, useful as medicament or food or feed additive, comprising dietary fiber component and ahypocholesterolemic agent, e.g. statin |
| 08/12/2004 | DE10303527A1 Stable suspensions of carotenoids, retinoids and/or unsaturated fatty acids, useful as additives in food, feed, pharmaceutical or cosmetic preparations, containing insoluble ascorbate salt particles as antioxidant |
| 08/12/2004 | DE10303196A1 Use of products that release nitric oxide in vivo to treat or prevent infectious diseases in humans or animals |
| 08/12/2004 | CA2831207A1 Caprazene compounds and derivatives thereof |
| 08/12/2004 | CA2831202A1 Caprazene compounds and derivatives thereof |
| 08/12/2004 | CA2812356A1 Caprazene and derivatives thereof |
| 08/12/2004 | CA2773659A1 Caprazene compounds and derivatives thereof |
| 08/12/2004 | CA2726147A1 Caprazene and derivatives thereof |
| 08/12/2004 | CA2573363A1 Liquid pharmaceutical formulations of palonosetron |
| 08/12/2004 | CA2573241A1 Liquid pharmaceutical formulations of palonosetron |
| 08/12/2004 | CA2573228A1 Liquid pharmaceutical formulations of palonosetron |
| 08/12/2004 | CA2573194A1 Liquid pharmaceutical formulations of palonosetron |
| 08/12/2004 | CA2515585A1 Enteric sustained-release fine particles for tamsulosin or its salt and manufacturing method thereof |
| 08/12/2004 | CA2514931A1 Oligosaccharide derivative |
| 08/12/2004 | CA2514653A1 Uses of integrin alphavbeta3 antagonists |
| 08/12/2004 | CA2514612A1 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
| 08/12/2004 | CA2514581A1 Methods of treating lower urinary tract disorders using sodium channel modulators |
| 08/12/2004 | CA2514575A1 Crystal of (23s)-1.alpha.-hydroxy-27-nor-25-methylenevitamin d3-26,23-lactone and process for producing the same |
| 08/12/2004 | CA2514574A1 Use of sodium channel modulators for treating gastrointestinal tract disorders |
| 08/12/2004 | CA2514573A1 Thiazole derivatives and their use as vap-1 inhibitors |
| 08/12/2004 | CA2514551A1 Slowly digestible starch |
| 08/12/2004 | CA2514547A1 Receptor agonists |
| 08/12/2004 | CA2514536A1 Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes |
| 08/12/2004 | CA2514474A1 Freeze-dried fibrin matrices and methods for preparation thereof |
| 08/12/2004 | CA2514396A1 Compositions and methods containing substituted quinolines and substituted diphenylsulfones |
| 08/12/2004 | CA2514327A1 Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin |
| 08/12/2004 | CA2514252A1 A therapeutic composition for the treatment of hiv-1 and hiv-2 |
| 08/12/2004 | CA2514177A1 Tolerance-induced targeted antibody production |
| 08/12/2004 | CA2514125A1 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| 08/12/2004 | CA2514117A1 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| 08/12/2004 | CA2514109A1 Improved formulations for transmucosal vaginal delivery of bisphosphonates |
| 08/12/2004 | CA2514066A1 Sensitive proteasome sensor constructs and methods for their design and use |
| 08/12/2004 | CA2514048A1 Improved jasmine aromachemicals |
| 08/12/2004 | CA2514047A1 Spermicidal and/or antifungal composition and methods of using the same |
| 08/12/2004 | CA2513975A1 A method of treating breast cancer with androgen receptor antagonists |
| 08/12/2004 | CA2513893A1 Multiparticulate compositions of milnacipran for oral administration |
| 08/12/2004 | CA2513884A1 Controlled release of highly soluble agents |
| 08/12/2004 | CA2513759A1 Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same |
| 08/12/2004 | CA2513753A1 Crystalline form of nateglinide |
| 08/12/2004 | CA2513712A1 Osteogenic composition |
| 08/12/2004 | CA2513706A1 Compositions and methods for improving recovery after general anesthesia |
| 08/12/2004 | CA2513641A1 Substituted heterocyclic compounds |
| 08/12/2004 | CA2513398A1 Antisense oligonucleotides that inhibit expression of hif-1 |
| 08/12/2004 | CA2512879A1 N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| 08/12/2004 | CA2512559A1 A rapid-acting pharmaceutical composition |
| 08/12/2004 | CA2511941A1 Aryl alkyl carbamate derivatives production and use thereof in therapy |
| 08/12/2004 | CA2511080A1 Fatigue reducing agent |
| 08/12/2004 | CA2509807A1 Powder pharmaceutical compositions |
| 08/11/2004 | EP1445317A2 Compositions and methods for the diagnosis and treatment of tumor |
| 08/11/2004 | EP1445312A1 Method of inhibiting gene expression |
| 08/11/2004 | EP1445259A1 Process and crystal forms of 2-methyl-thieno-benzodiazepine |
| 08/11/2004 | EP1445258A1 Activator for peroxisome proliferator-activated receptor delta |
| 08/11/2004 | EP1445256A1 Carboxylic acid derivative compounds and drugs containing the same as the active ingredient |
| 08/11/2004 | EP1445252A1 Sulphonamide derivatives, the preparation thereof and the application of same as medicaments |
| 08/11/2004 | EP1445250A1 Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same |
| 08/11/2004 | EP1445249A1 Novel bensophenone derivatives or salts thereof |
| 08/11/2004 | EP1444988A1 Anticancer agents |
| 08/11/2004 | EP1444984A1 Topical pharmaceutical compositions containing natural active constituents suitable for the prevention and treatment of mucosal inflammation processes |
| 08/11/2004 | EP1444983A1 Agents for treating inflammatory bowel diseases |
| 08/11/2004 | EP1444982A1 The use of purine derivatives as selective kinase inhibitors |
| 08/11/2004 | EP1444981A1 Intracellular calcium concentration increase inhibitors |